NASDAQ:BMRN BioMarin Pharmaceutical (BMRN) Stock Price, News & Analysis $55.75 -0.20 (-0.36%) Closing price 10/26/2026 04:00 PM EasternExtended Trading$56.00 +0.25 (+0.46%) As of 07:06 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About BioMarin Pharmaceutical Stock (NASDAQ:BMRN) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get BMRN alerts:Sign Up Key Stats Today's Range$55.34▼$56.8950-Day Range$54.38▼$69.3352-Week Range$49.26▼$70.98Volume2.36 million shsAverage Volume2.46 million shsMarket Capitalization$10.79 billionP/E Ratio150.68Dividend YieldN/APrice Target$88.60Consensus RatingModerate Buy Company Overview BioMarin Pharmaceutical Inc. is a biotechnology company focused on developing and commercializing therapies for serious and life-threatening rare diseases. The company’s research and development efforts center on genetic and metabolic disorders, where patient populations are often small and treatment options are limited. BioMarin’s marketed products include Voxzogo (vosoritide) for children with achondroplasia and open growth plates, Palynziq (pegvaliase) and Kuvan (sapropterin dihydrochloride) for phenylketonuria, Brineura (cerliponase alfa) for late-infantile neuronal ceroid lipofuscinosis type 2, Vimizim (elosulfase alfa) for Morquio A syndrome, and Naglazyme (galsulfase) for mucopolysaccharidosis VI. The company also markets Roctavian, a gene therapy for certain adults with severe hemophilia A. Founded in 1997 and headquartered in San Rafael, California, BioMarin serves patients and healthcare providers in the United States and international markets. Its products are generally distributed through specialized healthcare and reimbursement channels because of the complex nature of the diseases they address. Alexander Hardy serves as the company’s chief executive officer.AI Generated. May Contain Errors. Read More BioMarin Pharmaceutical Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks87th Percentile Overall ScoreBMRN MarketRank™: 4.340038935755 of 5 starsBioMarin Pharmaceutical scored higher than 87% of companies evaluated by MarketBeat, and ranked 33rd out of 907 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingBioMarin Pharmaceutical has received a consensus rating of Moderate Buy. The company's average rating score is 2.81, and is based on 3 strong buy ratings, 16 buy ratings, 6 hold ratings, and 1 sell rating.Upside PotentialBioMarin Pharmaceutical has a consensus price target of $88.60, representing about 58.9% upside from its current price of $55.75.Amount of Analyst CoverageBioMarin Pharmaceutical has been the subject of 14 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about BioMarin Pharmaceutical's stock forecast and price target. Earnings and Valuation3.1 / 5Proj. Earnings Growth105.02% Earnings GrowthEarnings for BioMarin Pharmaceutical are expected to grow by 105.02% in the coming year, from $2.59 to $5.31 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of BioMarin Pharmaceutical is 150.68, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 25.87.Price to Earnings Ratio vs. SectorThe P/E ratio of BioMarin Pharmaceutical is 150.68, which means that it is trading at a more expensive P/E ratio than the Healthcare sector average P/E ratio of about 34.71.Price to Earnings Growth RatioBioMarin Pharmaceutical has a PEG Ratio of 0.61. PEG Ratios below 1 indicate that a company could be undervalued.Price to Book Value per Share RatioBioMarin Pharmaceutical has a P/B Ratio of 1.76. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about BioMarin Pharmaceutical's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted6.27% of the float of BioMarin Pharmaceutical has been sold short.Short Interest Ratio / Days to CoverBioMarin Pharmaceutical has a short interest ratio ("days to cover") of 4.9.Change versus previous monthShort interest in BioMarin Pharmaceutical has recently increased by 4.58%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBioMarin Pharmaceutical does not currently pay a dividend.Dividend GrowthBioMarin Pharmaceutical does not have a long track record of dividend growth. News and Social Media3.3 / 5News Sentiment0.34 News SentimentBioMarin Pharmaceutical has a news sentiment score of 0.34. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.60 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 21 news articles for BioMarin Pharmaceutical this week, compared to 8 articles on an average week.Search Interest19 people have searched for BMRN on MarketBeat in the last 30 days. This is an increase of 73% compared to the previous 30 days.MarketBeat Follows7 people have added BioMarin Pharmaceutical to their MarketBeat watchlist in the last 30 days. This is an increase of 250% compared to the previous 30 days. Company Ownership0.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, BioMarin Pharmaceutical insiders have not sold or bought any company stock.Percentage Held by Insiders0.68% of the stock of BioMarin Pharmaceutical is held by insiders.Percentage Held by Institutions98.71% of the stock of BioMarin Pharmaceutical is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about BioMarin Pharmaceutical's insider trading history. Receive BMRN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BioMarin Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BMRN Stock News HeadlinesBioMarin to Host Third Quarter 2026 Financial Results Conference Call and Webcast on Monday, November 2, 2026, at 4:30pm ETOctober 26 at 9:00 AM | prnewswire.comBioMarin CEO Alexander Hardy: We're an at-scale leader in rare diseasesOctober 26 at 8:59 AM | cnbc.comTwo charts tell you the future…Gold miners are posting record cash flows, outperforming every other sector, yet mining still makes up just 1% of global equities. Garrett Goggin, CFA, CMT, has spent more than 20 years studying gold cycles and mining companies. Porter Stansberry has called him the most knowledgeable gold investor in the world.October 27 at 1:00 AM | Golden Portfolio (Ad)BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Stock Has Average Price Target of $88.60October 26 at 2:15 AM | americanbankingnews.comMorgan Stanley Issues Pessimistic Forecast for BioMarin Pharmaceutical (NASDAQ:BMRN) Stock PriceOctober 23, 2026 | americanbankingnews.comBioMarin Pharmaceutical (BMRN) Gets a Buy from Piper SandlerOctober 22, 2026 | theglobeandmail.comBioMarin Pharmaceutical (NASDAQ:BMRN) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst SaysOctober 22, 2026 | americanbankingnews.comBioMarin Pharmaceutical (NASDAQ:BMRN) Earns "Overweight" Rating from Cantor FitzgeraldOctober 22, 2026 | americanbankingnews.comSee More Headlines BMRN Stock Analysis - Frequently Asked Questions How have BMRN shares performed this year? BioMarin Pharmaceutical's stock was trading at $59.43 at the start of the year. Since then, BMRN stock has decreased by 6.2% and is now trading at $55.75. How were BioMarin Pharmaceutical's earnings last quarter? BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced its quarterly earnings data on Thursday, August, 6th. The biotechnology company reported $1.20 earnings per share for the quarter, topping the consensus estimate of $0.95 by $0.25. The business's revenue was up 20.0% compared to the same quarter last year. Read the conference call transcript. Who are BioMarin Pharmaceutical's major shareholders? BioMarin Pharmaceutical's top institutional investors include Assenagon Asset Management S.A. (0.69%), Fort Washington Investment Advisors Inc. OH (0.37%), Robeco Institutional Asset Management B.V. (0.12%) and Apollon Wealth Management LLC (0.05%). Insiders that own company stock include Jean Jacques Bienaime, Henry J Fuchs, Jeffrey Robert Ajer, Charles Greg Guyer, Brian Mueller, George Eric Davis, Gregory R Friberg, Cristin Hubbard and Erin Burkhart. View institutional ownership trends. How do I buy shares of BioMarin Pharmaceutical? Shares of BMRN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of BioMarin Pharmaceutical own? Based on aggregate information from My MarketBeat watchlists, some other companies that BioMarin Pharmaceutical investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Micron Technology (MU), Gilead Sciences (GILD), Salesforce (CRM), Vertex Pharmaceuticals (VRTX) and Regeneron Pharmaceuticals (REGN). Company Calendar Last Earnings8/06/2026Today10/27/2026Next Earnings (Estimated)11/02/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (1m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 BMRN's financial health is in the Yellow zone, according to TradeSmith. BMRN has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:BMRN CIK1048477 Webwww.biomarin.com Phone(415) 506-6700Fax415-382-7889Employees3,221Year Founded1997Price Target and Rating Average Price Target for BioMarin Pharmaceutical$88.60 High Price Target$122.00 Low Price Target$60.00 Potential Upside/Downside+58.9%Consensus RatingModerate Buy Rating Score (0-4)2.81 Research Coverage26 Analysts Profitability EPS (Trailing Twelve Months)$0.37 Trailing P/E Ratio150.68 Forward P/E Ratio21.53 P/E Growth0.61Net Income$348.90 million Net Margins2.14% Pretax Margin4.38% Return on Equity5.32% Return on Assets3.69% Debt Debt-to-Equity Ratio0.56 Current Ratio2.39 Quick Ratio1.32 Sales & Book Value Annual Sales$3.22 billion Price / Sales3.35 Cash Flow$2.84 per share Price / Cash Flow19.61 Book Value$31.68 per share Price / Book1.76Miscellaneous Outstanding Shares193,570,000Free Float192,258,000Market Cap$10.79 billion OptionableOptionable Beta0.22 Social Links 10 Best Stocks to Own in Fall 2026AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.Get This Free Report This page (NASDAQ:BMRN) was last updated on 10/26/2026 by MarketBeat.com Staff. From Our Partners80 Days Until America's Rare Earth Supply Chain ShiftChina controls more than 90% of global rare earth alloy production, leverage it is using to restrict exports t...The Tomorrow Investor | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredMy next big call (under $1)17,556% on KDA. 3,900% on PRE. 2,650% on OCEAN. Every single one of these was recommended to our community bef...Crypto 101 Media | SponsoredHe turned $12K into $1.65M without touching Apple or TeslaTim Sykes turned $12,415 in gift money into more than $1.65 million before graduating college, without trading...Tim Sykes | SponsoredA Simple Guide to Options Trading While It's Still FreeA free copy of Options Trading Made Simple is available now but wont stay that way for long. Chris Rowe cal...True Market Insiders | SponsoredTwo charts tell you the future…Gold miners are posting record cash flows, outperforming every other sector, yet mining still makes up just 1%...Golden Portfolio | SponsoredLast call for your free 0DTE reportThe 0DTE Game Plan lays out a simple 3-step framework for trading same-day options: Plan it, profit from it, p...Profits Run | SponsoredWhy Gerardo Del Real says wait before buying uranium stocksGerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he ...Digest Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioMarin Pharmaceutical Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioMarin Pharmaceutical With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
